- OVIDE Lotion is flammable. The lotion and wet hair should not be
exposed to open flames or electric heat sources, including hair dryers and
electric curlers. Do not smoke while applying lotion or while hair is wet.
Allow hair to dry naturally and to remain uncovered after application of OVIDE
- OVIDE Lotion should only be used on children under the direct supervision
of an adult.
- If OVIDE Lotion comes into contact with the eyes, flush immediately with
water. Consult a physician if eye irritation persists.
- If skin irritation occurs, discontinue use of product until irritation clears.
Reapply the OVIDE Lotion, and if irritation reoccurs, consult a physician.
- Chemical burns including second-degree burns and stinging sensations may
occur with the use of OVIDE Lotion.
Keep out of reach of children. Close eyes tightly during product application.
If accidentally placed in the eye, flush immediately with water. Use only on
There are no special laboratory tests needed in order to use this medication.
Carcinogenesis, Mutagenesis, and Impairment of Fertility
Carcinogenesis, mutagenesis and impairment of fertility have not been studied
with OVIDE Lotion (0.5% pharmaceutical grade malathion). However, followi ng
long-term oral administration of technical grade malathion to rodents via dietary
supplementation, increased incidences of hepatocellular neoplastic lesions were
observed in B6C3F1 mice dosed for 18 months at malathion doses greater than
1500 mg/kg/day, and in female F344 rats dosed for 2 years at malathion doses
greater than 4 00 mg/kg/day. These tumors occurred only in association with
severe hepatic toxicity and chronic suppression of acetylcholinesterase activity,
or at doses causing excessive mortality. Based on body surface area, doses at
which carcinogenic effects were observed in rodents following life-time exposures
to malathion were approximately 14- to 26-fold greater than the maximum dose
anticipated in a 10 kg child following a single use of OVIDE Lotion, assumi
ng 100% bioavailability. Actual systemic exposures are expected to be less than
10% of the administered dose.
The malathion of greater than pharmaceutical-grade purity used in OVIDE Lotion
has not been tested for genotoxicity. The technical-grade malathion (95% pure)
was found to be negative in Salmonella typhimurium, equivocally positive in
the mouse lymphoma cell assay, and positive in in vitro chromosomal aberration
and sister chromatid exchange assays. Fifteen separate in vitro gene
mutation studies with malathion of unknown purity have reported negative results,
while three studies reported malathion to be mutagenic in bacterial cells. Both
technical grade (94–96.5%) and purified (98-99%) malathion have been reported
to cause chromosomal aberrations and sist er chromatid exchanges in vitro
in human and hamster cell lines. In vivo chromosomal aberration and micronucleus
studies of technical-grade malathion are reported to be positive, whereas an
in vivo chromosomal aberration study of > 99% pure malathion was reported
to be negative. Furthermore, mice exposed to malathion in their drinking wate
r for 7 weeks demonstrated no evidence of chromosome damage in bone marrow cells,
spermatogonia, or primary spermatocytes. Lack of details makes independent evaluation
of the results of these assays impossible. Ashby and Purchase have suggested
that impurities may be responsible for some of the observed genetic activity
Reproduction studies performed with malathion in rats at doses over 180 fold
greater than those anticipated in a 60 kg adult (based on body surface area
and assuming 100% bioavailability) revealed no evidence of impaired fertility.
Pregnancy Category B. There was no evidence of teratogenicity in studies in
rats and rabbits at doses up to 900 mg/kg/day and 100 mg/kg/day malathion, respectively.
A study in rats failed to show any gross fetal abnormalities attributable to
feeding malathion up to 2,500 ppm (~ 200 mg/kg/day) in the diet during a three
- generation evaluation period. These doses were approximately 40 to 180 times
higher than the dose anticipated in a 60 kg adult (based on body surface area
and assuming 100% bioavailability). Because animal reproduction studies are
not always predictive of human responses, this drug should be used (or handled)
during pregnancy only if clearly needed.
Malathion in an acetone vehicle has been reported to be absorbed through human
skin to the extent of 8% of the applied dose. However, percutaneous absorption
from the OVIDE® (malathion) Lotion, 0.5% formulation has not been studied,
and it is not known whether malathion is excreted in human milk. Because many
drugs are excreted in h uman milk, caution should be exercised when OVIDE Lotion
is administered to (or handled by) a nursing mother.
The safety and effectiveness of OVIDE Lotion in children less than 6 years
of age has not been established via well-controlled trials.
No information provided.